PDF's Last Days In US: Industry Works To Solve Its FDA Application Problem

The goal is a platform where sponsors could enter data that multiple regulators could view in real-time, rather than rely on ‘digital paper’ – pdfs and other static file formats that require health agencies to reenter the data in order to analyze it.

Public Meeting: Modernizing FDA Data Strategy virtual meeting — FDA PRINCIPAL DEPUTY COMMISSIONER AMY ABERNETHY WAS AMONG THE PARTICIPANTS AT THE AGENCY'S 30 JUNE PUBLIC MEETING ON MODERNIZING ITS DATA STRATEGY.

A group of pharma companies is working to potentially streamline application submission and assessment by ending their reliance on so-called digital paper.

The project, known as Accumulus, involves creating a platform that would allow for rolling data flow, instead of the boluses...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

US Tariff Overhang Weighs on Chinese API Exports

03 Jul 2025

• By Dexter Jie Yan

Chinese API exports to US fell 24% year-on-year to $255m in May, when US and China called a truce in a previously escalating trade war.

Pharma Still Nervous While Riding Trump’s Tariff Rollercoaster

10 Apr 2025

• By Jessica Merrill

The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.

Over The Counter: What To Expect From The 61st AESGP Annual Meeting, With Jurate Švarcaite

24 Mar 2025

• By David Ridley

HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.

Bayer Consumer Health Expands North America And LATAM Supply Capacity

17 Jan 2025

Bayer is investing $52m in its Lerma, Mexico manufacturing site, which the firm said will enable it to increase production of key OTC brands like Aspirin and Alka-Seltzer from 100m to 140m units by 2030.

Green Regulation Is ‘A Baseline Not A Burden’ – Behind Opella’s B Corp Journey

21 Jul 2025

• By David Ridley

“For us, regulation is the floor, not the ceiling,” Opella's chief sustainability officer Marissa Saretsky tells HBW Insight as the firm gains B Corp Certification. Other topics covered in this exclusive interview include Opella's position on the revised Urban Wastewater Treatment Directive.